Key Takeaways
- Genvor, Inc. publishes peer-reviewed research validating AGM182 antifungal peptide in PhytoFrontiers™
- Study conducted with USDA-ARS demonstrates 76–98% reduction in aflatoxin contamination
- Research shows no adverse effects on plant growth or yield
- Publication follows issuance of U.S. Patent No. 12,458,684 for AGM182 transgenic corn
- Technology targets Aspergillus flavus and Fusarium species linked to major crop losses
Genvor, Inc. Reports Peer-Reviewed Results for AGM182 Technology
Genvor, Inc. (OTCQB: GNVR), an AI-driven peptide technology company focused on sustainable agriculture, announced the publication of peer-reviewed research validating its proprietary AGM182 antifungal peptide technology. The study appears in PhytoFrontiers™, a journal of the American Phytopathological Society.
Conducted in collaboration with the United States Department of Agriculture’s Agricultural Research Service (USDA-ARS), the research evaluated transgenic corn expressing AGM182 for resistance to Aspergillus flavus and associated aflatoxin contamination.
Greenhouse trial results reported:
- 76–98% reduction in total aflatoxin contamination
- No observed adverse effects on plant growth or yield
- A demonstrated mammalian safety profile with no observed toxicity
- Activity against both Aspergillus flavus and Fusarium species
Aflatoxins are toxic compounds produced by Aspergillus flavus that can contaminate corn and other crops. Annual economic losses from fungal diseases in U.S. corn are estimated between $3 billion and $5 billion, with aflatoxin contamination contributing potential market impacts ranging from $52 million in lower-risk years to $1.68 billion in high-risk years.
Genvor, Inc. Strengthens Intellectual Property Position
The publication follows Genvor, Inc.’s November 2025 announcement that the United States Patent and Trademark Office issued U.S. Patent No. 12,458,684 covering transgenic corn expressing AGM182. The patent is co-assigned with the USDA.
Chad Pawlak, Chief Executive Officer of Genvor, stated: “This publication confirms that our BioCypher™ Algorithm can design peptides that deliver meaningful, measurable results against some of agriculture’s most costly challenges.”
Dr. Jesse Jaynes, Professor of Biochemistry at Tuskegee University and founding scientist behind Genvor’s technologies, added:
“Seeing AGM182 validated through rigorous peer review in PhytoFrontiers confirms that computationally designed peptides can provide durable, safe, and scalable solutions for pre-harvest crop protection.”
Genvor, Inc. Advances Collaborative Research with USDA
The research was conducted at the USDA-ARS Food and Feed Safety Research Unit in New Orleans in collaboration with scientists from Tuskegee University and Genvor, Inc. The work builds on a seven-year Cooperative Research and Development Agreement (CRADA) between Genvor and USDA-ARS focused on developing corn varieties resistant to pre-harvest aflatoxin contamination.
According to Genvor, Inc., the combination of patent protection and peer-reviewed validation supports ongoing efforts to advance licensing discussions and commercial development of AGM182 technology for agricultural markets.
Read the complete study.
